David Guyer, MD - Venture Partner

Focus: Biotechnology

Summary:
David Guyer joined SVLS in 2006.

Prior Experience:
David co-founded and served as CEO and director for six years of Eyetech Pharmaceuticals (former Ticker 'EYET') , Inc. a biopharmaceutical company that specialized in the development and commercialization of novel therapeutics to treat diseases of the eye. He led the firm through private financing rounds totaling approximately $170 million, a $157 million initial public offering and a secondary financing. The company also developed and gained FDA approval for Macugen, a product to treat macular degeneration, which Eyetech partnered with Pfizer in a deal valued at over $750 million. OSI Pharmaceuticals subsequently acquired Eyetech in a deal valued at $935 million. Prior to founding Eyetech, Dr. Guyer was professor and chairman of the department of ophthalmology at the NYU School of Medicine.

Qualifications:
. David received a BSc from Yale College and an MD from Johns Hopkins Medical School.